Sinnott Catherine J, Cogswell III Lawrence P, Johnson Anthony, Strichartz Gary R
Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, Massachussets 02115, USA.
Anesthesiology. 2003 Jan;98(1):181-8. doi: 10.1097/00000542-200301000-00028.
Adding epinephrine to lidocaine solutions for peripheral nerve block potentiates and prolongs the action, but by incompletely understood mechanisms. In an effort to discriminate the pharmacokinetic from the pharmacodynamic effects of epinephrine, the authors measured the lidocaine content of peripheral nerve over the course of block produced by 0.5% lidocaine, with and without epinephrine, and correlated it with the degree of analgesia.
Percutaneous sciatic nerve blocks were performed in 18 groups of rats (10 in each) with 0.1 ml of either 0.5% lidocaine or 0.5% lidocaine with epinephrine (1:100,000). Over the full course of nerve block, the authors regularly measured analgesia to toe pinch and then rapidly removed nerves to assay intraneural lidocaine content at 2-120 min after injection.
The kinetics of lidocaine's clearance from nerve was composed of a fast-decaying transient superimposed on a very slowly decaying component. The effect of epinephrine on the intraneural lidocaine content was to increase the amount of lidocaine in the slow-decaying component by threefold to fourfold, although the total neural content was not altered by epinephrine for the first 10 min after injection. Epinephrine prolonged blockade by almost fourfold and enhanced the intensity of peak analgesia, as well as the fraction of rats with complete block, almost throughout the 2-120-min period of behavioral observation.
Adding epinephrine to lidocaine solutions increases the intensity and duration of sciatic nerve block in the rat. The early increase in intensity is not matched with an increase in intraneural lidocaine content at these early times, although the prolonged duration of block by epinephrine appears to correspond to an enlarged lidocaine content in nerve at later times, as if a very slowly emptying "effector compartment" received a larger share of the dose. The increase in early analgesia without increased lidocaine content may be explained by a pharmacodynamic action of epinephrine that transiently enhances lidocaine's potency, but also by a pharmacokinetic effect that alters the distribution of the same net content of lidocaine within the nerve.
在用于周围神经阻滞的利多卡因溶液中添加肾上腺素可增强并延长其作用,但作用机制尚不完全清楚。为了区分肾上腺素的药代动力学和药效学作用,作者测量了在有和没有肾上腺素的情况下,由0.5%利多卡因产生的神经阻滞过程中周围神经内的利多卡因含量,并将其与镇痛程度相关联。
对18组大鼠(每组10只)进行经皮坐骨神经阻滞,每组注射0.1 ml的0.5%利多卡因或含肾上腺素(1:100,000)的0.5%利多卡因。在神经阻滞的全过程中,作者定期测量对夹趾的镇痛效果,然后迅速取出神经,测定注射后2至120分钟神经内利多卡因的含量。
利多卡因从神经中清除的动力学由叠加在非常缓慢衰减成分上的快速衰减瞬态组成。肾上腺素对神经内利多卡因含量的影响是使缓慢衰减成分中的利多卡因量增加三至四倍,尽管注射后最初10分钟内肾上腺素并未改变神经内利多卡因的总量。在行为观察的2至120分钟期间,肾上腺素几乎将阻滞时间延长了四倍,并增强了峰值镇痛强度以及完全阻滞大鼠的比例。
在利多卡因溶液中添加肾上腺素可增加大鼠坐骨神经阻滞的强度和持续时间。早期强度的增加在这些早期并未伴随着神经内利多卡因含量的增加,尽管肾上腺素延长的阻滞持续时间似乎与后期神经内利多卡因含量的增加相对应,就好像一个排空非常缓慢的“效应室”接受了更大比例的剂量。早期镇痛增加而利多卡因含量未增加可能是由于肾上腺素的药效学作用暂时增强了利多卡因的效力,也可能是由于药代动力学效应改变了神经内相同利多卡因净含量的分布。